Your session is about to expire
← Back to Search
Durvalumab for Lung Cancer (ATLANTIC Trial)
ATLANTIC Trial Summary
This trial will study the effects of the drug durvalumab in patients with non small cell lung cancer that has spread to other parts of the body. The trial will assess how well the drug works, as well as its safety and tolerability.
ATLANTIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowATLANTIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 713 Patients • NCT02125461ATLANTIC Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What risks have been associated with MEDI4736?
"MEDI4736 is reasonably safe, having earned a score of 2. This reflects the fact that there have been several trials conducted to test its safety but none studying its efficacy yet."
Can participants younger than two decades old partake in this research endeavor?
"Potential participants must meet the eligibility requirements, which stipulate that they must be between 18 and 130 years of age."
To what medical conditions is MEDI4736 typically prescribed?
"MEDI4736 can be used to treat those with unresectable stage III non-small cell lung cancer, untreated metastatic ureteral carcinoma and any prior exposure."
To what extent is the patient population engaged in this clinical trial?
"This clinical study has ceased recruiting patients, with its last edit on October 17th 2022. If you are seeking alternatives for participation, there are 2045 trials actively enrolling people suffering from lung cancer and 333 studies hoping to recruit participants into the MEDI4736 trial."
Could I be considered a valid participant for this investigation?
"This trial is recruiting 446 participants aged 18 and higher, who have been diagnosed with lung cancer. In order to be eligible for the trial, these patients must have had a previous platinum-based chemotherapy treatment as well as another additional regimen for their NSCLC, possess an estimated life expectancy of more than 12 weeks, and display a World Health Organisation (WHO) Performance Status score of 0 or 1."
Is this research recruiting new test subjects?
"The records on clinicaltrials.gov indicate that this research initiative is not recruiting participants right now, despite first being posted in February of 2014 and last edited October 17th 2022. Although the trial has concluded its recruitment phase, there are 2378 other studies actively taking candidates at present."
Are there any additional experiments that have been completed using MEDI4736?
"Currently, there are 333 clinical studies investigating MEDI4736 with 52 of these trials being in their final phase. The majority of the research taking place is located in Cordoba, Texas though 12952 sites across the world are running tests on this drug."
Are there multiple locations offering this experiment within the US?
"Currently, 32 sites are taking on new participants for this trial. These locations range from Middleton to Port Saint Lucie and New Haven. To decrease the burden of travel, those enrolled should select a site near them if possible."
Share this study with friends
Copy Link
Messenger